




# **DIAGNOSTIC IMAGING**

## **MUSCULOSKELETAL: NON-TRAUMATIC DISEASE**



**MANASTER • ROBERTS • PETERSILGE**  
**Moore • Hanrahan • Crim**





# DIAGNOSTIC IMAGING

## MUSCULOSKELETAL: NON-TRAUMATIC DISEASE

**B.J. Manaster, MD, PhD**

Professor of Radiology  
University of Utah School of Medicine  
Salt Lake City, UT

**Catherine C. Roberts, MD**

Associate Dean, Mayo School of Health Sciences  
Associate Professor of Radiology  
Consultant Radiologist  
Mayo Clinic  
Scottsdale, AZ

**Cheryl A. Petersilge, MD**

Chair, Department of Radiology  
Hillcrest Hospital  
Vice-Chair, Regional Radiology  
Imaging Institute  
Cleveland Clinic Health System

Cleveland, OH



New York, NY

**Christopher J. Hanrahan, MD, PhD**

Assistant Professor of Radiology  
University of Utah School of Medicine  
Salt Lake City, UT

**Julia Crim, MD**

Chief of Musculoskeletal Radiology  
Professor of Radiology  
University of Utah School of Medicine  
Salt Lake City, UT



AMIRSYS®

Names you know. Content you trust.®

© 2010 Amirsys, Inc.

Compilation © 2010 Amirsys Publishing, Inc.

All rights reserved. No portion of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or media or by any means, electronic, mechanical, optical, photocopying, recording, or otherwise, without prior written permission from the respective copyright holders.

Printed in Canada by Friesens, Altona, Manitoba, Canada

ISBN: 978-1-931884-79-2

## Notice and Disclaimer

The information in this product ("Product") is provided as a reference for use by licensed medical professionals and no others. It does not and should not be construed as any form of medical diagnosis or professional medical advice on any matter. Receipt or use of this Product, in whole or in part, does not constitute or create a doctor-patient, therapist-patient, or other healthcare professional relationship between the copyright holders and any recipient. This Product may not reflect the most current medical developments, and the copyright holders (individually and jointly), make no claims, promises, or guarantees about accuracy, completeness, or adequacy of the information contained in or linked to the Product. The Product is not a substitute for or replacement of professional medical judgment. The copyright holders, and their affiliates, authors, contributors, partners, and sponsors, individually and jointly, disclaim all liability or responsibility for any injury and/or damage to persons or property in respect to actions taken or not taken based on any and all Product information.

In the cases where drugs or other chemicals are prescribed, readers are advised to check the Product information currently provided by the manufacturer of each drug to be administered to verify the recommended dose, the method and duration of administration, and contraindications. It is the responsibility of the treating physician relying on experience and knowledge of the patient to determine dosages and the best treatment for the patient.

To the maximum extent permitted by applicable law, the copyright holders provide the Product AS IS AND WITH ALL FAULTS, AND HEREBY DISCLAIMS ALL WARRANTIES AND CONDITIONS, WHETHER EXPRESS, IMPLIED OR STATUTORY, INCLUDING BUT NOT LIMITED TO, ANY (IF ANY) IMPLIED WARRANTIES OR CONDITIONS OF MERCHANTABILITY, OF FITNESS FOR A PARTICULAR PURPOSE, OF LACK OF VIRUSES, OR ACCURACY OR COMPLETENESS OF RESPONSES, OR RESULTS, AND OF LACK OF NEGLIGENCE OR LACK OF WORKMANLIKE EFFORT. ALSO, THERE IS NO WARRANTY OR CONDITION OF TITLE, QUIET ENJOYMENT, QUIET POSSESSION, CORRESPONDENCE TO DESCRIPTION OR NON-INFRINGEMENT, WITH REGARD TO THE PRODUCT. THE ENTIRE RISK AS TO THE QUALITY OF OR ARISING OUT OF USE OR PERFORMANCE OF THE PRODUCT REMAINS WITH THE READER.

The respective copyright holders, individually and jointly, disclaim all warranties of any kind if the Product was customized, repackaged or altered in any way by any third party.

## Library of Congress Cataloging-in-Publication Data

Diagnostic imaging. Musculoskeletal : non-traumatic disease / B.J. Manaster ... [et al.].

p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-931884-79-2

1. Musculoskeletal system--Imaging--Handbooks, manuals, etc. 2. Musculoskeletal system--Imaging--Atlases. I. Manaster, B. J. [DNLM: 1. Musculoskeletal Diseases--diagnosis--Handbooks. 2. Diagnosis, Differential--Handbooks. 3. Diagnostic Imaging--methods--Handbooks. 4. Musculoskeletal System--radiography--Handbooks. WE 39 D5385 2010]

RC925.5.D537 2010

616.7'0754--dc22

2010016359

# ACKNOWLEDGEMENTS

## Text Editing

Kellie J. Heap  
Arthur G. Gelsinger, MA  
Katherine Riser, MA  
Dave L. Chance, MA

## Image Editing

Jeffrey J. Marmorstone  
Danny C. La

## Medical Editing

Robert W. Hastings, III, MD

## Illustrations

Richard Coombs, MS  
Lane R. Bennion, MS  
Laura C. Sesto, MA

## Art Direction and Design

Laura C. Sesto, MA

## Associate Editor

Ashley R. Renlund, MA

## Production Lead

Melissa A. Hoopes

Some images were previously published in Manaster BJ, May DA, Disler DG. Musculoskeletal Imaging: The Requisites. 2nd ed. Philadelphia, PA: Mosby, Elsevier, 2002. Each of these images is identified by "MSK Req" in the caption.

These images appear as follows: section.page.image; 1.61.2; 1.139.2; 1.166.1; 5.28.1; 2.12.3; 2.12.4; 2.15.1; 2.15.2; 2.41.5; 2.106.3; 2.142.1; and 2.157.4.



AMIRSYS<sup>®</sup>

Names you know. Content you trust.<sup>®</sup>

# TABLE OF CONTENTS

## SECTION 1 Arthritis

### Introduction and Overview

Introduction to Arthritis	1-2
<i>B.J. Manaster, MD, PhD, FACR</i>	

### Erosive

Rheumatoid Arthritis of Axial Skeleton	1-8
<i>B.J. Manaster, MD, PhD, FACR</i>	
Rheumatoid Arthritis of Shoulder and Elbow	1-14
<i>B.J. Manaster, MD, PhD, FACR</i>	
Rheumatoid Arthritis of Wrist and Hand	1-20
<i>B.J. Manaster, MD, PhD, FACR</i>	
Rheumatoid Arthritis of Hip	1-26
<i>B.J. Manaster, MD, PhD, FACR</i>	
Rheumatoid Arthritis of Knee	1-30
<i>B.J. Manaster, MD, PhD, FACR</i>	
Rheumatoid Arthritis of Ankle and Foot	1-34
<i>B.J. Manaster, MD, PhD, FACR</i>	
Robust Rheumatoid Arthritis	1-38
<i>B.J. Manaster, MD, PhD, FACR</i>	
Felty Syndrome	1-39
<i>B.J. Manaster, MD, PhD, FACR</i>	
Juvenile Idiopathic Arthritis (JIA)	1-40
<i>B.J. Manaster, MD, PhD, FACR</i>	
Adult Still Disease	1-46
<i>B.J. Manaster, MD, PhD, FACR</i>	

### Productive

Osteoarthritis of Axial Skeleton	1-48
<i>B.J. Manaster, MD, PhD, FACR</i>	
DISH	1-52
<i>B.J. Manaster, MD, PhD, FACR</i>	
OPLL	1-58
<i>B.J. Manaster, MD, PhD, FACR</i>	
Osteoarthritis of Shoulder and Elbow	1-62
<i>B.J. Manaster, MD, PhD, FACR</i>	
Osteoarthritis of Wrist and Hand	1-66
<i>B.J. Manaster, MD, PhD, FACR</i>	
Osteoarthritis of Hip	1-70
<i>B.J. Manaster, MD, PhD, FACR</i>	

Osteoarthritis of Knee	1-76
<i>B.J. Manaster, MD, PhD, FACR</i>	

### Mixed Erosive and Productive

Ankylosing Spondylitis	1-82
<i>B.J. Manaster, MD, PhD, FACR</i>	
Inflammatory Bowel Disease Arthritis	1-88
<i>B.J. Manaster, MD, PhD, FACR</i>	
Psoriatic Arthritis	1-94
<i>B.J. Manaster, MD, PhD, FACR</i>	
Chronic Reactive Arthritis	1-100
<i>B.J. Manaster, MD, PhD, FACR</i>	

### Due to Biochemical Disorders or Depositional Disease

Gout	1-106
<i>B.J. Manaster, MD, PhD, FACR</i>	
Pyrophosphate Arthropathy	1-112
<i>B.J. Manaster, MD, PhD, FACR</i>	
Hydroxyapatite Deposition Disease	1-118
<i>B.J. Manaster, MD, PhD, FACR</i>	
Amyloid Deposition	1-124
<i>B.J. Manaster, MD, PhD, FACR</i>	
Hemochromatosis	1-130
<i>B.J. Manaster, MD, PhD, FACR</i>	
Ochronosis	1-131
<i>B.J. Manaster, MD, PhD, FACR</i>	
Wilson Disease	1-132
<i>B.J. Manaster, MD, PhD, FACR</i>	
Oxalosis	1-133
<i>B.J. Manaster, MD, PhD, FACR</i>	

### Miscellaneous Joint Disorders

Pigmented Villonodular Synovitis (PVNS)	1-134
<i>B.J. Manaster, MD, PhD, FACR</i>	
Intraarticular Chondroma	1-140
<i>B.J. Manaster, MD, PhD, FACR</i>	
Nodular Synovitis (Intraarticular)	1-144
<i>B.J. Manaster, MD, PhD, FACR</i>	
Multicentric Reticulohistiocytosis	1-148
<i>B.J. Manaster, MD, PhD, FACR</i>	
Synovial Hemangioma	1-149
<i>B.J. Manaster, MD, PhD, FACR</i>	



Synovial Chondromatosis	1-150	Periosteal Chondroma	2-94
<i>B.J. Manaster, MD, PhD, FACP</i>		<i>B.J. Manaster, MD, PhD, FACP</i>	
Charcot (Neuropathic)	1-156	Chondrosarcoma	2-100
<i>B.J. Manaster, MD, PhD, FACP</i>		<i>B.J. Manaster, MD, PhD, FACP</i>	
Hypertrophic Osteoarthropathy	1-162	Dedifferentiated Chondrosarcoma	2-106
<i>B.J. Manaster, MD, PhD, FACP</i>		<i>B.J. Manaster, MD, PhD, FACP</i>	
Complex Regional Pain Syndrome	1-168	Periosteal Chondrosarcoma	2-108
<i>B.J. Manaster, MD, PhD, FACP</i>		<i>B.J. Manaster, MD, PhD, FACP</i>	

## SECTION 2

### Osseous Tumors and Tumor-like Conditions

#### Introduction and Overview

Bone Tumors: Diagnosis, Staging, and Biopsy	2-2
<i>B.J. Manaster, MD, PhD, FACP</i>	
Bone Tumors: Treatment Options and Follow-Up	2-10
<i>B.J. Manaster, MD, PhD, FACP</i>	

#### Bone-Forming Tumors

Enostosis (Bone Island)	2-16
<i>B.J. Manaster, MD, PhD, FACP</i>	
Osteoma	2-20
<i>B.J. Manaster, MD, PhD, FACP</i>	
Osteoid Osteoma	2-26
<i>B.J. Manaster, MD, PhD, FACP</i>	
Osteoblastoma	2-32
<i>B.J. Manaster, MD, PhD, FACP</i>	
Conventional Osteosarcoma	2-38
<i>B.J. Manaster, MD, PhD, FACP</i>	
Parosteal Osteosarcoma	2-44
<i>B.J. Manaster, MD, PhD, FACP</i>	
Periosteal Osteosarcoma	2-50
<i>B.J. Manaster, MD, PhD, FACP</i>	
Telangiectatic Osteosarcoma	2-54
<i>B.J. Manaster, MD, PhD, FACP</i>	
Low-Grade Intraosseous Osteosarcoma	2-58
<i>B.J. Manaster, MD, PhD, FACP</i>	
High-Grade Surface Osteosarcoma	2-62
<i>B.J. Manaster, MD, PhD, FACP</i>	
Secondary Osteosarcoma	2-64
<i>B.J. Manaster, MD, PhD, FACP</i>	

#### Cartilage-Forming Tumors

Enchondroma	2-68
<i>B.J. Manaster, MD, PhD, FACP</i>	
Osteochondroma	2-74
<i>B.J. Manaster, MD, PhD, FACP</i>	
Multiple Hereditary Exostoses	2-80
<i>B.J. Manaster, MD, PhD, FACP</i>	
Chondroblastoma	2-86
<i>B.J. Manaster, MD, PhD, FACP</i>	
Chondromyxoid Fibroma	2-90
<i>B.J. Manaster, MD, PhD, FACP</i>	

#### Marrow Tumors

Plasmacytoma	2-110
<i>Chris Hanrahan, MD, PhD</i>	
Multiple Myeloma	2-114
<i>Chris Hanrahan, MD, PhD</i>	
POEMS	2-120
<i>B.J. Manaster, MD, PhD, FACP</i>	
Ewing Sarcoma	2-122
<i>B.J. Manaster, MD, PhD, FACP</i>	
Leukemia: Osseous Manifestations	2-128
<i>B.J. Manaster, MD, PhD, FACP</i>	
Lymphoma of Bone	2-132
<i>B.J. Manaster, MD, PhD, FACP</i>	
Metastases: Bone Marrow	2-138
<i>B.J. Manaster, MD, PhD, FACP</i>	

#### Other Osseous Tumors

Desmoplastic Fibroma	2-144
<i>B.J. Manaster, MD, PhD, FACP</i>	
Liposclerosing Myxofibrous Tumor	2-146
<i>B.J. Manaster, MD, PhD, FACP</i>	
Malignant Fibrous Histiocytoma of Bone	2-148
<i>B.J. Manaster, MD, PhD, FACP</i>	
Fibrosarcoma	2-152
<i>B.J. Manaster, MD, PhD, FACP</i>	
Intraosseous Lipoma	2-154
<i>B.J. Manaster, MD, PhD, FACP</i>	
Giant Cell Tumor	2-158
<i>B.J. Manaster, MD, PhD, FACP</i>	
Adamantinoma	2-164
<i>B.J. Manaster, MD, PhD, FACP</i>	
Hemangioma: Intraosseous	2-168
<i>B.J. Manaster, MD, PhD, FACP</i>	
Hemangiopericytoma: Osseous	2-174
<i>B.J. Manaster, MD, PhD, FACP</i>	
Hemangioendothelioma: Osseous	2-175
<i>B.J. Manaster, MD, PhD, FACP</i>	
Angiosarcoma: Osseous	2-176
<i>B.J. Manaster, MD, PhD, FACP</i>	
Chordoma	2-180
<i>B.J. Manaster, MD, PhD, FACP</i>	

## Tumor-like Conditions

Paget Disease	2-184
<i>B.J. Manaster, MD, PhD, FACR</i>	
Langerhans Cell Histiocytosis	2-190
<i>B.J. Manaster, MD, PhD, FACR</i>	
Fibrous Dysplasia	2-196
<i>B.J. Manaster, MD, PhD, FACR</i>	
Osteofibrous Dysplasia	2-202
<i>B.J. Manaster, MD, PhD, FACR</i>	
Simple Bone Cyst	2-206
<i>B.J. Manaster, MD, PhD, FACR</i>	
Aneurysmal Bone Cyst	2-212
<i>B.J. Manaster, MD, PhD, FACR</i>	
Fibroxanthoma	2-218
<i>B.J. Manaster, MD, PhD, FACR</i>	
Trevor Fairbank	2-222
<i>B.J. Manaster, MD, PhD, FACR</i>	

## Radiation-Induced Abnormalities

Radiation-Induced Complications of the Skeleton	2-224
<i>B.J. Manaster, MD, PhD, FACR</i>	

# SECTION 3 Soft Tissue Tumors

## Introduction and Overview

Introduction to Soft Tissue Tumors	3-2
<i>Catherine C. Roberts, MD</i>	

## Adipocytic Tumors

### Benign Adipocytic Tumors

Lipoma: Soft Tissue	3-10
<i>Catherine C. Roberts, MD</i>	
Lipomatosis	3-16
<i>Catherine C. Roberts, MD</i>	
Lipomatosis: Nerve	3-22
<i>Catherine C. Roberts, MD</i>	
Macrodystrophia Lipomatosa	3-26
<i>Catherine C. Roberts, MD</i>	
Lipoma Arborescens: Knee	3-30
<i>Catherine C. Roberts, MD</i>	
Lipoblastoma/Lipoblastomatosis	3-34
<i>Catherine C. Roberts, MD</i>	
Hibernoma	3-36
<i>Catherine C. Roberts, MD</i>	
Parosteal Lipoma	3-40
<i>Catherine C. Roberts, MD</i>	

### Intermediate Adipocytic Tumors

Atypical Lipomatous Tumor	3-44
<i>Catherine C. Roberts, MD</i>	

## Malignant Adipocytic Tumors

Myxoid Liposarcoma	3-48
<i>Catherine C. Roberts, MD</i>	
Pleomorphic Liposarcoma	3-52
<i>Catherine C. Roberts, MD</i>	
Dedifferentiated Liposarcoma	3-53
<i>Catherine C. Roberts, MD</i>	

## Fibroblastic/Myoblastic Tumors

### Benign Fibrous Tumors

Nodular and Proliferative Fasciitis	3-54
<i>Catherine C. Roberts, MD</i>	
Bizarre Parosteal Osteochondromatous Proliferation	3-55
<i>Catherine C. Roberts, MD</i>	
Elastofibroma	3-56
<i>Catherine C. Roberts, MD</i>	
Fibrous Hamartoma of Infancy	3-60
<i>Catherine C. Roberts, MD</i>	
Myofibroma/Myofibromatosis	3-61
<i>Catherine C. Roberts, MD</i>	
Fibromatosis Colli	3-62
<i>Catherine C. Roberts, MD</i>	
Juvenile Hyaline Fibromatosis	3-63
<i>Catherine C. Roberts, MD</i>	
Fibroma of Tendon Sheath	3-64
<i>Catherine C. Roberts, MD</i>	
Desmoplastic Fibroblastoma	3-68
<i>Catherine C. Roberts, MD</i>	
Calcifying Aponeurotic Fibroma	3-70
<i>Catherine C. Roberts, MD</i>	

### Intermediate (Locally Aggressive) Fibrous Tumors

Superficial Fibromatoses	3-72
<i>Catherine C. Roberts, MD</i>	
Desmoid-Type Fibromatosis	3-76
<i>Catherine C. Roberts, MD</i>	

### Intermediate (Rarely Metastasizing) Fibrohistiocytic Tumors

Solitary Fibrous Tumor and Hemangiopericytoma	3-82
<i>Catherine C. Roberts, MD</i>	
Inflammatory Myofibroblastic Tumor	3-88
<i>Catherine C. Roberts, MD</i>	
Infantile Fibrosarcoma	3-92
<i>Catherine C. Roberts, MD</i>	

### Malignant Fibrous Tumors

Fibrosarcoma: Soft Tissue	3-94
<i>Catherine C. Roberts, MD</i>	
Myxofibrosarcoma	3-98
<i>Catherine C. Roberts, MD</i>	
Low-Grade Fibromyxoid Sarcoma	3-102
<i>Catherine C. Roberts, MD</i>	

Sclerosing Epithelioid Fibrosarcoma <i>Catherine C. Roberts, MD</i>	3-104	<b>Intermediate (Rarely Metastasizing) Vascular Tumors</b>	
<b>So-called Fibrohistiocytic Tumors</b>		Kaposi Sarcoma <i>Catherine C. Roberts, MD</i>	3-168
<b>Benign Fibrohistiocytic Tumors</b>		Hemangioendothelioma: Soft Tissue <i>Catherine C. Roberts, MD</i>	3-172
Giant Cell Tumor Tendon Sheath <i>Catherine C. Roberts, MD</i>	3-108	<b>Malignant Vascular Tumors</b>	
Diffuse-Type Giant Cell Tumor (Extraarticular PVNS) <i>Catherine C. Roberts, MD</i>	3-114	Angiosarcoma: Soft Tissue <i>Catherine C. Roberts, MD</i>	3-174
Deep Benign Fibrous Histiocytoma <i>Catherine C. Roberts, MD</i>	3-116	<b>Chondroosseous Tumors</b>	
<b>Malignant Fibrohistiocytic Tumors</b>		Chondroma: Soft Tissue <i>Catherine C. Roberts, MD</i>	3-176
Undifferentiated Pleomorphic Sarcoma <i>Catherine C. Roberts, MD</i>	3-118	Extraskeletal Mesenchymal Chondrosarcoma <i>Catherine C. Roberts, MD</i>	3-178
Undifferentiated Pleomorphic Sarcoma with Prominent Inflammation <i>Catherine C. Roberts, MD</i>	3-122	Extraskeletal Osteosarcoma <i>Catherine C. Roberts, MD</i>	3-180
Dermatofibrosarcoma Protuberans <i>Catherine C. Roberts, MD</i>	3-124	<b>Tumors of Uncertain Differentiation</b>	
<b>Smooth Muscle Tumors</b>		<b>Benign Tumors of Uncertain Differentiation</b>	
<b>Smooth Muscle Tumors, Benign</b>		Intramuscular Myxoma <i>Catherine C. Roberts, MD</i>	3-184
Angioleiomyoma <i>Catherine C. Roberts, MD</i>	3-128	<b>Intermediate Tumors (Rarely Metastasizing) of Uncertain Differentiation</b>	
Leiomyoma: Superficial and Deep <i>Catherine C. Roberts, MD</i>	3-130	Ossifying Fibromyxoid Tumor <i>Catherine C. Roberts, MD</i>	3-188
<b>Smooth Muscle Tumors, Malignant</b>		<b>Malignant Tumors of Uncertain Differentiation</b>	
Leiomyosarcoma <i>Catherine C. Roberts, MD</i>	3-134	Synovial Sarcoma <i>Catherine C. Roberts, MD</i>	3-190
<b>Pericytic (Perivascular) Tumors</b>		Epithelioid Sarcoma <i>Catherine C. Roberts, MD</i>	3-196
Glomus Tumor <i>Catherine C. Roberts, MD</i>	3-140	Extraskeletal Myxoid Chondrosarcoma <i>Catherine C. Roberts, MD</i>	3-200
<b>Skeletal Muscle Tumors</b>		PNET/Extraskeletal Ewing Sarcoma <i>Catherine C. Roberts, MD</i>	3-204
<b>Skeletal Muscle Tumors, Benign</b>		<b>Peripheral Nerve Sheath Tumors</b>	
Rhabdomyoma <i>Catherine C. Roberts, MD</i>	3-144	<b>Nonneoplastic</b>	
<b>Skeletal Muscle Tumors, Malignant</b>		Morton Neuroma <i>Catherine C. Roberts, MD</i>	3-206
Rhabdomyosarcoma <i>Catherine C. Roberts, MD</i>	3-146	Traumatic Neuroma <i>Catherine C. Roberts, MD</i>	3-210
<b>Vascular &amp; Lymphatic Tumors</b>		<b>Neurofibroma</b>	
<b>Benign Vascular Tumors</b>		Neurofibroma <i>Catherine C. Roberts, MD</i>	3-212
Hemangioma and Vascular Malformations: Soft Tissue <i>Catherine C. Roberts, MD</i>	3-152	<b>Schwannoma</b>	
Angiomatosis <i>Catherine C. Roberts, MD</i>	3-158	Schwannoma <i>Catherine C. Roberts, MD</i>	3-218
Klippel-Trenaunay-Weber Syndrome <i>Catherine C. Roberts, MD</i>	3-160	<b>Malignant Peripheral Nerve Sheath Tumor</b>	
Lymphangioma <i>Catherine C. Roberts, MD</i>	3-164	Malignant Peripheral Nerve Sheath Tumor <i>Catherine C. Roberts, MD</i>	3-224



## Skin and Subcutaneous Lesions

Epidermal Inclusion Cyst	3-228
<i>Catherine C. Roberts, MD</i>	
Rheumatoid Nodule	3-230
<i>Catherine C. Roberts, MD</i>	
Metastases: Soft Tissue	3-234
<i>Catherine C. Roberts, MD</i>	
Melanoma	3-238
<i>Catherine C. Roberts, MD</i>	

## Soft Tissue Tumor Mimics

Soft Tissue Tumor Mimics: Infection/ Inflammation	3-244
<i>Catherine C. Roberts, MD</i>	
Soft Tissue Tumor Mimics: Vascular	3-248
<i>Catherine C. Roberts, MD</i>	
Soft Tissue Tumor Mimics: Crystal Disease	3-252
<i>Catherine C. Roberts, MD</i>	
Soft Tissue Tumor Mimics: Other	3-256
<i>Catherine C. Roberts, MD</i>	
Myositis Ossificans/Heterotopic Ossification	3-262
<i>B.J. Manaster, MD, PhD, FACR</i>	
Xanthoma	3-268
<i>Catherine C. Roberts, MD</i>	

## SECTION 4 Congenital and Developmental Abnormalities

### General

Arthrogryposis	4-2
<i>B.J. Manaster, MD, PhD, FACR</i>	
Amniotic Band Syndrome	4-3
<i>B.J. Manaster, MD, PhD, FACR</i>	
Cerebral Palsy	4-4
<i>B.J. Manaster, MD, PhD, FACR</i>	
Down Syndrome (Trisomy 21)	4-5
<i>B.J. Manaster, MD, PhD, FACR</i>	
Fibrodysplasia Ossificans Progressiva	4-6
<i>B.J. Manaster, MD, PhD, FACR</i>	
Muscular Dystrophy	4-7
<i>B.J. Manaster, MD, PhD, FACR</i>	
Neurofibromatosis	4-8
<i>B.J. Manaster, MD, PhD, FACR</i>	
Osteogenesis Imperfecta	4-14
<i>B.J. Manaster, MD, PhD, FACR</i>	
Turner Syndrome	4-20
<i>B.J. Manaster, MD, PhD, FACR</i>	

### Upper Extremity

Glenoid Hypoplasia	4-21
<i>B.J. Manaster, MD, PhD, FACR</i>	
Madelung Deformity	4-22
<i>B.J. Manaster, MD, PhD, FACR</i>	

Ulnar Variance	4-26
<i>B.J. Manaster, MD, PhD, FACR</i>	

## Lower Extremity

Developmental Dysplasia of the Hip	4-30
<i>B.J. Manaster, MD, PhD, FACR</i>	
Femoral Acetabular Impingement Morphology	4-36
<i>B.J. Manaster, MD, PhD, FACR</i>	
Slipped Capital Femoral Epiphysis	4-42
<i>B.J. Manaster, MD, PhD, FACR</i>	
Proximal Femoral Focal Deficiency	4-48
<i>B.J. Manaster, MD, PhD, FACR</i>	
Osgood-Schlatter Disease	4-52
<i>B.J. Manaster, MD, PhD, FACR</i>	
Sinding Larsen Johansson Disease	4-53
<i>B.J. Manaster, MD, PhD, FACR</i>	
Blount Disease	4-54
<i>B.J. Manaster, MD, PhD, FACR</i>	
Pes Planus (Flatfoot)	4-56
<i>B.J. Manaster, MD, PhD, FACR</i>	
Club Foot (Talipes Equinovarus)	4-62
<i>B.J. Manaster, MD, PhD, FACR</i>	
Congenital Vertical Talus (Rocker Bottom Foot)	4-66
<i>B.J. Manaster, MD, PhD, FACR</i>	
Pes Cavus	4-67
<i>B.J. Manaster, MD, PhD, FACR</i>	
Tarsal Coalition	4-68
<i>B.J. Manaster, MD, PhD, FACR</i>	

## SECTION 5 Dysplasias

### Skeletal Dysplasia Dwarfism Dysplasia

Introduction to Dwarfing Dysplasias	5-2
<i>Cheryl A. Petersilge, MD</i>	
Achondroplasia	5-6
<i>Cheryl A. Petersilge, MD</i>	
Pseudoachondroplasia	5-10
<i>Cheryl A. Petersilge, MD</i>	
Achondrogenesis	5-11
<i>Cheryl A. Petersilge, MD</i>	
Thanatophoric Dwarfism	5-12
<i>Cheryl A. Petersilge, MD</i>	
Asphyxiating Thoracic Dystrophy of Jeune	5-14
<i>Cheryl A. Petersilge, MD</i>	
Chondroectodermal Dysplasia (Ellis-van Creveld)	5-15
<i>Cheryl A. Petersilge, MD</i>	
Spondyloepiphyseal Dysplasia	5-16
<i>Cheryl A. Petersilge, MD</i>	
Multiple Epiphyseal Dysplasia	5-20
<i>Cheryl A. Petersilge, MD</i>	

## Nondwarfing Dysplasias

Ollier Disease	5-24
<i>Cheryl A. Petersilge, MD</i>	
Maffucci Syndrome	5-28
<i>Cheryl A. Petersilge, MD</i>	
Chondrodysplasia Punctata	5-29
<i>Cheryl A. Petersilge, MD</i>	
Cleidocranial Dysplasia	5-30
<i>Cheryl A. Petersilge, MD</i>	
Caffey Disease	5-31
<i>Cheryl A. Petersilge, MD</i>	
Fong Disease (Nail Patella Syndrome)	5-32
<i>Cheryl A. Petersilge, MD</i>	

## Sclerosing Dysplasias

Melorheostosis	5-34
<i>Cheryl A. Petersilge, MD</i>	
Progressive Diaphyseal Dysplasia	5-38
<i>Cheryl A. Petersilge, MD</i>	
Osteopetrosis	5-42
<i>Cheryl A. Petersilge, MD</i>	
Pycnodysostosis	5-48
<i>Cheryl A. Petersilge, MD</i>	
Osteitis Condensans	5-52
<i>Cheryl A. Petersilge, MD</i>	
Osteitis Pubis: Nontraumatic Origin	5-54
<i>Cheryl A. Petersilge, MD</i>	
Intramedullary Osteosclerosis	5-56
<i>Cheryl A. Petersilge, MD</i>	
Other Sclerosing Conditions of Bone	5-57
<i>Cheryl A. Petersilge, MD</i>	

## SECTION 6 Systemic Diseases with MSK Involvement

### General

Complications of Paraplegia	6-2
<i>B.J. Manaster, MD, PhD, FACP</i>	
Acroosteolysis	6-6
<i>B.J. Manaster, MD, PhD, FACP</i>	
Sickle Cell Anemia	6-10
<i>B.J. Manaster, MD, PhD, FACP</i>	
Thalassemia	6-16
<i>B.J. Manaster, MD, PhD, FACP</i>	
Myelofibrosis	6-20
<i>B.J. Manaster, MD, PhD, FACP</i>	
Hemophilia	6-22
<i>B.J. Manaster, MD, PhD, FACP</i>	
Diabetes	6-28
<i>B.J. Manaster, MD, PhD, FACP</i>	
HIV-AIDS	6-34
<i>B.J. Manaster, MD, PhD, FACP</i>	

Sarcoidosis: Bone	6-40
<i>Sandra Moore, MD</i>	
Sarcoidosis: Muscle	6-44
<i>Sandra Moore, MD</i>	
Sarcoidosis: Joint	6-46
<i>Sandra Moore, MD</i>	
Sarcoidosis: Soft Tissue	6-47
<i>Sandra Moore, MD</i>	
Mastocytosis	6-48
<i>B.J. Manaster, MD, PhD, FACP</i>	
Tuberous Sclerosis	6-49
<i>B.J. Manaster, MD, PhD, FACP</i>	

## Storage Disorders

Gaucher Disease	6-50
<i>B.J. Manaster, MD, PhD, FACP</i>	
Mucopolysaccharidoses	6-54
<i>B.J. Manaster, MD, PhD, FACP</i>	
Erdheim-Chester Disease	6-56
<i>B.J. Manaster, MD, PhD, FACP</i>	

## Connective Tissue Disorders

Systemic Lupus Erythematosus	6-58
<i>B.J. Manaster, MD, PhD, FACP</i>	
Progressive Systemic Sclerosis	6-62
<i>B.J. Manaster, MD, PhD, FACP</i>	
Inflammatory Myopathy	6-66
<i>B.J. Manaster, MD, PhD, FACP</i>	
Overlap Syndrome/Mixed Connective Tissue Disease	6-70
<i>B.J. Manaster, MD, PhD, FACP</i>	

## Connective Tissue Disorder with Arachnodactyly

Homocystinuria	6-71
<i>B.J. Manaster, MD, PhD, FACP</i>	
Marfan and Ehlers-Danlos	6-72
<i>B.J. Manaster, MD, PhD, FACP</i>	

## Soft Tissue Disorders

Denervation Hypertrophy	6-74
<i>Cheryl A. Petersilge, MD</i>	

## Vascular

Embolic Disease	6-76
<i>B.J. Manaster, MD, PhD, FACP</i>	
Meningococcemia	6-77
<i>B.J. Manaster, MD, PhD, FACP</i>	

## SECTION 7 Orthopedic Implants or Arthrodesis

### Arthroplasties and Arthrodesis

Introduction to Arthroplasties	7-2
<i>B.J. Manaster, MD, PhD, FACP</i>	

Hip Implant	7-10	Soft Tissue Infection	8-30
<i>B.J. Manaster, MD, PhD, FACR</i>		<i>B.J. Manaster, MD, PhD, FACR</i>	
Revision Arthroplasty	7-16	Necrotizing Fasciitis	8-34
<i>B.J. Manaster, MD, PhD, FACR</i>		<i>B.J. Manaster, MD, PhD, FACR</i>	
Knee Implant	7-20		
<i>B.J. Manaster, MD, PhD, FACR</i>			
Shoulder Implant	7-26		
<i>B.J. Manaster, MD, PhD, FACR</i>			
Elbow Implant	7-30		
<i>B.J. Manaster, MD, PhD, FACR</i>			
Ankle Implant	7-32		
<i>B.J. Manaster, MD, PhD, FACR</i>			
Ankle Arthrodesis	7-34		
<i>Julia Crim, MD</i>			
Small Joint Implants/Arthrodesis	7-36		
<i>B.J. Manaster, MD, PhD, FACR</i>			

## Internal Fixation

Hallux Valgus Corrections	7-42	Tuberculosis	8-36
<i>Julia Crim, MD</i>		<i>Cheryl A. Petersilge, MD</i>	
Intramedullary Rod/Nail	7-44	Fungal Infection	8-42
<i>Cheryl A. Petersilge, MD</i>		<i>Cheryl A. Petersilge, MD</i>	
Plate Fixation	7-48	Brucellosis	8-43
<i>Cheryl A. Petersilge, MD</i>		<i>B.J. Manaster, MD, PhD, FACR</i>	
Screw Fixation	7-52	Madura Foot	8-44
<i>Cheryl A. Petersilge, MD</i>		<i>Cheryl A. Petersilge, MD</i>	
Cement & Bone Fillers	7-58	Rocky Mountain Spotted Fever	8-45
<i>Cheryl A. Petersilge, MD</i>		<i>B.J. Manaster, MD, PhD, FACR</i>	
Wire/Cerclage/Cable Fixation	7-64	Leprosy	8-46
<i>Cheryl A. Petersilge, MD</i>		<i>B.J. Manaster, MD, PhD, FACR</i>	
Anchoring Devices	7-65	Syphilis	8-47
<i>Cheryl A. Petersilge, MD</i>		<i>B.J. Manaster, MD, PhD, FACR</i>	
		Polio	8-48
		<i>B.J. Manaster, MD, PhD, FACR</i>	
		Parasitic Infection	8-49
		<i>Cheryl A. Petersilge, MD</i>	

## SECTION 8 Infection

### Osteomyelitis

Acute Osteomyelitis: Child	8-2		
<i>Cheryl A. Petersilge, MD</i>			
Acute Osteomyelitis: Adult	8-6		
<i>B.J. Manaster, MD, PhD, FACR</i>			
Spinal Infections	8-12		
<i>Cheryl A. Petersilge, MD</i>			
Chronic Osteomyelitis	8-18		
<i>Cheryl A. Petersilge, MD</i>			

### Soft Tissue and Joints

Septic Arthritis	8-22		
<i>B.J. Manaster, MD, PhD, FACR</i>			
Infectious Tenosynovitis	8-28		
<i>B.J. Manaster, MD, PhD, FACR</i>			
Infectious Bursitis	8-29		
<i>B.J. Manaster, MD, PhD, FACR</i>			

## Specific Pathogens

## Conditions of Unknown Etiology

SAPHO	8-50
<i>Cheryl A. Petersilge, MD</i>	
Chronic Recurrent Multifocal Osteomyelitis	8-51
<i>B.J. Manaster, MD, PhD, FACR</i>	

## SECTION 9 Bone Marrow

### Distribution Pattern

Marrow Distribution: Normal	9-2
<i>Sandra Moore, MD</i>	
Increased or Decreased Marrow Cellularity	9-6
<i>Sandra Moore, MD</i>	
Diffuse Marrow Infiltration and Replacement	9-12
<i>Sandra Moore, MD</i>	
Focal Marrow Infiltration and Replacement	9-18
<i>Sandra Moore, MD</i>	

## SECTION 10 Bone Marrow Edema and Necrosis

### Introduction and Overview

Introduction to Osteonecrosis	10-2
<i>Cheryl A. Petersilge, MD</i>	

## Bone Marrow Edema

Transient Bone Marrow Edema and Regional Migratory Osteoporosis	10-6
<i>Cheryl A. Petersilge, MD</i>	

## Osteonecrosis

Osteonecrosis of Hip	10-8
<i>Cheryl A. Petersilge, MD</i>	
Osteonecrosis of Shoulder	10-14
<i>Cheryl A. Petersilge, MD</i>	
Osteonecrosis of Knee	10-15
<i>Cheryl A. Petersilge, MD</i>	
Osteonecrosis of Wrist	10-16
<i>Cheryl A. Petersilge, MD</i>	
Osteonecrosis of Ankle and Foot	10-20
<i>Cheryl A. Petersilge, MD</i>	
Legg-Calve-Perthes	10-24
<i>B.J. Manaster, MD, PhD, FACP</i>	

## SECTION 11 Metabolic Bone Disease

### Introduction and Overview

Introduction to Metabolic Bone Disease	11-2
<i>Cheryl A. Petersilge, MD</i>	

### Diseases of Calcium Homeostasis

Hyperparathyroidism	11-8
<i>Cheryl A. Petersilge, MD</i>	
Osteomalacia and Rickets	11-14
<i>Cheryl A. Petersilge, MD</i>	
Renal Osteodystrophy	11-18
<i>Cheryl A. Petersilge, MD</i>	
Dialysis-Related Disease, Metastatic Calcification	11-24
<i>Cheryl A. Petersilge, MD</i>	
Dialysis-Related Disease, Spondyloarthropathy	11-25
<i>Cheryl A. Petersilge, MD</i>	
Hypoparathyroidism, Pseudo- & Pseudopseudohypoparathyroidism	11-26
<i>Cheryl A. Petersilge, MD</i>	

## Osteoporosis

Primary Osteoporosis	11-28
<i>Cheryl A. Petersilge, MD</i>	
Disuse Osteoporosis	11-32
<i>Cheryl A. Petersilge, MD</i>	
Idiopathic Juvenile Osteoporosis	11-33
<i>Cheryl A. Petersilge, MD</i>	
Anorexia	11-34
<i>B.J. Manaster, MD, PhD, FACP</i>	
Osteoporosis: Other Causes	11-35
<i>Cheryl A. Petersilge, MD</i>	

## Pituitary Disorders

Pituitary Disorders: Acromegaly and Growth Hormone Deficiency	11-36
<i>Cheryl A. Petersilge, MD</i>	

## Thyroid Disease

Hypothyroidism and Cretinism	11-38
<i>Cheryl A. Petersilge, MD</i>	
Hyperthyroidism	11-40
<i>Cheryl A. Petersilge, MD</i>	
Thyroid Acropachy	11-41
<i>Cheryl A. Petersilge, MD</i>	

## Miscellaneous Metabolic Conditions

Hypophosphatasia	11-42
<i>Cheryl A. Petersilge, MD</i>	
Cushing Syndrome	11-44
<i>Cheryl A. Petersilge, MD</i>	
Tumoral (Idiopathic) Calcinosis	11-45
<i>Cheryl A. Petersilge, MD</i>	

## SECTION 12 Drug-Induced and Nutritional MSK Conditions

### Drug-Induced Conditions

Steroids: Complications	12-2
<i>B.J. Manaster, MD, PhD, FACP</i>	
Alcohol: Complications	12-3
<i>B.J. Manaster, MD, PhD, FACP</i>	
Vitamin A: Complications	12-4
<i>B.J. Manaster, MD, PhD, FACP</i>	
Vitamin D: Complications	12-5
<i>B.J. Manaster, MD, PhD, FACP</i>	
Fluoride: Complications	12-6
<i>B.J. Manaster, MD, PhD, FACP</i>	
Retinoid-associated Osteoarthritis	12-7
<i>B.J. Manaster, MD, PhD, FACP</i>	
Lead Poisoning	12-8
<i>B.J. Manaster, MD, PhD, FACP</i>	
Warfarin (Coumadin): Complications	12-9
<i>B.J. Manaster, MD, PhD, FACP</i>	
Bisphosphonates: Complications	12-10
<i>Cheryl A. Petersilge, MD</i>	

### Nutritional Deficiency

Scurvy	12-11
<i>B.J. Manaster, MD, PhD, FACP</i>	



# **SECTION 1**

## **Arthritis**

### **Introduction and Overview**

Introduction to Arthritis	1-2
---------------------------	-----

### **Erosive**

Rheumatoid Arthritis of Axial Skeleton	1-8
Rheumatoid Arthritis of Shoulder and Elbow	1-14
Rheumatoid Arthritis of Wrist and Hand	1-20
Rheumatoid Arthritis of Hip	1-26
Rheumatoid Arthritis of Knee	1-30
Rheumatoid Arthritis of Ankle and Foot	1-34
Robust Rheumatoid Arthritis	1-38
Felty Syndrome	1-39
Juvenile Idiopathic Arthritis (JIA)	1-40
Adult Still Disease	1-46

### **Productive**

Osteoarthritis of Axial Skeleton	1-48
DISH	1-52
OPLL	1-58
Osteoarthritis of Shoulder and Elbow	1-62
Osteoarthritis of Wrist and Hand	1-66
Osteoarthritis of Hip	1-70
Osteoarthritis of Knee	1-76

### **Mixed Erosive and Productive**


Ankylosing Spondylitis	1-82
Inflammatory Bowel Disease Arthritis	1-88
Psoriatic Arthritis	1-94
Chronic Reactive Arthritis	1-100

### **Due to Biochemical Disorders or Depositional Disease**

Gout	1-106
Pyrophosphate Arthropathy	1-112
Hydroxyapatite Deposition Disease	1-118
Amyloid Deposition	1-124
Hemochromatosis	1-130
Ochronosis	1-131
Wilson Disease	1-132
Oxalosis	1-133

## Miscellaneous Joint Disorders

Pigmented Villonodular Synovitis (PVNS)	1-134
Intraarticular Chondroma	1-140
Nodular Synovitis (Intraarticular)	1-144
Multicentric Reticulohistiocytosis	1-148
Synovial Hemangioma	1-149
Synovial Chondromatosis	1-150
Charcot (Neuropathic)	1-156
Hypertrophic Osteoarthropathy	1-162
Complex Regional Pain Syndrome	1-168



## Classic Appearance of Arthritic Processes

When an arthritic process is well established in a particular patient, it will usually achieve a typical appearance, which allows diagnosis by means of imaging. At such a moderately early or midstage of disease, radiographs are usually sufficient to make the correct diagnosis. *The diagnosis usually depends on the location of the joint abnormalities and a host of other radiographic characteristics.*

**Location of involved joints** can often eliminate some diagnoses and raise the probability of others. For example, distal interphalangeal joint disease is commonly seen in psoriatic arthritis, osteoarthritis, and erosive osteoarthritis. However, it is not seen in rheumatoid arthritis; thus this diagnosis should not be considered. Similarly, a disease involving the sacroiliac joints would raise the possibility of ankylosing spondylitis, inflammatory bowel disease arthritis, psoriatic spondyloarthropathy, chronic reactive arthritis, osteoarthritis, and DISH. Common locations of joint involvement are illustrated in diagrammatic fashion in this section. Note the joints that are involved earliest and most commonly are distinguished from those involved less frequently or in end-stage disease.

While the location of the joints involved certainly contributes to establishing a list of reasonable diagnoses, the lists can be relatively long, as in the examples above. There are several other parameters that are useful in honing that list to a single diagnosis that are outlined in the tables that follow. Further explanation regarding some of these parameters may be helpful, as follows.

**Age and gender** may be the easiest parameters to apply. There are a minimal number of arthritic processes that affect children (juvenile inflammatory arthritis, hemophilic arthropathy, inflammatory bowel disease arthropathy, and septic joint) and teenagers (in addition to those affecting children, early onset adult rheumatoid arthritis and ankylosing spondylitis). Some diseases are gender specific (hemophilic arthropathy and hemochromatosis), while others are found in one gender far more frequently (gout, ankylosing spondylitis, chronic reactive arthritis in males, and rheumatoid arthritis in females).

One of the most important parameters is the **character of the process**. Some arthritides are **purely erosive**; rheumatoid arthritis is the hallmark for this group. Others are **purely bone-forming** (also termed "productive"). This bone formation may appear in the form of osteophytes (as in osteoarthritis), enthesopathy or ligamentous ossification (as in ankylosing spondylitis, DISH, and OPLL), or periostitis (as in psoriatic arthritis, chronic reactive arthritis, and juvenile idiopathic arthritis). Other processes may be **mixed**, sometimes starting with erosions but progressing to osteophytes (as in pyrophosphate arthropathy or gout) or starting with periostitis and progressing to mixed erosions and osteophytes (as in psoriatic arthritis or chronic reactive arthritis). These processes tend to be distinctive for each type of arthritis by the time they are well established; between evaluating the character of the process and its primary location in an individual, the diagnosis can usually be secured.

**Bilateral symmetry** of an arthritic process can be a useful characteristic. Rheumatoid arthritis is especially well known for appearing bilaterally symmetric. Note

that rheumatologists do not require specific joints of specific digits to qualify the arthritis as symmetric. For example, 5th PIP left hand and 3rd PIP right hand would be considered symmetric disease simply because of PIP involvement of each hand. Note also that bilateral symmetry may not be present in early stages of arthritic disease, even in rheumatoid arthritis. Similarly, while we usually think of the sacroiliitis of ankylosing spondylitis as being bilaterally symmetric, in its early stages the symmetry is often strikingly absent. Therefore, useful generalizations regarding bilateral symmetry are most often made in the mature stages of the disease process. However, rigid application of "rules" of symmetry should be avoided when evaluating early arthritis.

**Soft tissue swelling** can be the key to finding the earliest changes of arthritis on a radiograph. The sausage digit may lead to the discovery of subtle periostitis, even in the absence of joint space narrowing or erosions. Swelling around a metacarpophalangeal joint may lead to closer examination of a metacarpal head showing cortical indistinctness or the dot-dash pattern of early inflammatory disease. Be sure to window every image to evaluate the soft tissues, as these abnormalities can lead to closer examination of adjacent joints.

**Soft tissue masses** are not frequently seen in conjunction with arthritic processes. However, they may lead to specificity in diagnosis. Gouty tophi, seen as a mass containing a variable degree of dense tissue, can be diagnostic. As another example, soft tissue nodules, combined with acroosteolysis and interphalangeal joint erosions, leads to the rare diagnosis of multicentric reticulohistiocytosis.

In differentiating between the ligamentous ossification of DISH/OPLL, osteophytes of spondylosis deformans, syndesmophytes of ankylosing spondylitis, and paravertebral ossification of psoriatic arthritis and chronic reactive arthritis, the **character of paravertebral ossification** can often suggest the correct diagnosis. However, as with other parameters, it is important to note that mature paravertebral ossification in each of these entities may all have a similar appearance. True osteophytes may bridge across the disc space and give the appearance of the flowing ligamentous ossification of DISH. Mature ankylosing spondylitis has much bulkier syndesmophytes than the thin vertical ones depicted in early disease.

**Subchondral cysts** are seen in virtually all arthritic processes and therefore are rarely useful in differentiating among them. However, occasionally the subchondral cysts are so large that this characteristic becomes useful in diagnosis. Particularly large subchondral cysts in a setting that otherwise resembles rheumatoid arthritis lead to the diagnosis of robust rheumatoid arthritis. Very large cysts are also noted in pyrophosphate arthropathy and pigmented villonodular synovitis. Osteoarthritis and gout may also produce very large subchondral cysts.

**Bone density** must always be interpreted within the context of patient age and gender. An elderly female will usually have diffuse osteoporosis, with or without superimposed rheumatoid arthritis (classically described as causing juxtaarticular, followed by diffuse osteoporosis). Thus, though we state that normal bone density is a characteristic of osteoarthritis and gout, in an older patient those arthritic processes may be seen in the presence of diffuse osteoporosis. Another

example that may cause confusion is the young adult with end-stage renal disease and a renal transplant. Erosive disease in these patients is likely to be gout or amyloid. However, the bone density will be decreased due to both their renal osteodystrophy and likely use of steroids for their transplant. In this case, gout should be suggested to explain erosive disease, despite the bone appearing osteoporotic. Focal osteoporosis can also be helpful in identifying joints with active inflammation, as the hyperemia from the inflammatory process leaches the calcium from the bone.

The **pattern and timing of cartilage destruction** may be another useful parameter. Some arthritides, such as gout, classically cause prominent erosions before significant cartilage destruction, while most inflammatory arthritides, such as rheumatoid arthritis, result in early marginal erosions but also relatively early cartilage destruction. The pattern of cartilage destruction also distinguishes the inflammatory arthropathies, where it is uniform throughout the joint as opposed to the more focal cartilage destruction seen in the weight-bearing portions of the joint in osteoarthritis.

**Adjacent calcific or ossific densities** may be particularly helpful in diagnosis. Chondrocalcinosis is not unique to pyrophosphate arthropathy but is most frequently seen in that disease. The presence of chondrocalcinosis should also raise the question of traumatic osteoarthritis and hemochromatosis. Calcifications in gouty tophi are usually unique in their appearance. Calcific or ossific bodies in synovial chondromatosis are different from the osseous debris seen with a Charcot joint. Therefore, the character of adjacent calcific or osseous densities may be useful in the diagnostic process.

**Ankylosis** of the peripheral joints is most commonly seen in psoriatic arthritis and juvenile idiopathic arthritis. It is commonly found in the spine of patients suffering from spondyloarthropathies (most frequently ankylosing spondylitis), DISH, and juvenile idiopathic arthritis. Other more rare arthritic processes may show ankylosis as well. On the other hand, ankylosis in cases of rheumatoid arthritis is exceedingly rare. Do not be fooled by a surgical arthrodesis in a patient with severe rheumatoid arthritis. Arthrodesis is often attempted to stabilize the digits in this disease, and may mimic ankylosis.

## Early Appearance of Arthritic Processes

We are now diagnosing arthritic processes at an earlier stage, prior to any radiographic change. This ability is essential, since early application of disease-modifying drug therapy may halt joint destruction. The benefit of early diagnosis is obvious, yielding longer patient productivity and decreasing the need for arthroplasty. However, the diagnosis may be difficult with subtle or absent radiographic findings and relies on MR or ultrasound. Early tenosynovitis and joint effusions may be identified on ultrasound, and MR may demonstrate tenosynovitis, effusion, and bone marrow edema long before actual erosions are seen in rheumatoid arthritis. Inflammatory change at vertebral body corners may be identified on MR, indicating early spondyloarthropathy. Even more subtle may be the enthesitis and adjacent marrow edema found in early ankylosing spondylitis, which are often found at the "corners" of the image

(interspinous ligaments, iliac spine, greater trochanter) and are easily overlooked. Close attention should be paid to these locations, even when evaluating a "routine lower back pain" spine MR exam.

## Late Appearance of Arthritic Processes

End-stage arthritic processes may have a classic appearance. Classic changes are often seen in the deformities and erosive change in rheumatoid patients or in the postural changes with vertebral column fusion in ankylosing spondylitis patients. However, at times an arthritic process, particularly when ineffectively treated, may attain a potentially confusing nonstandard appearance. An example of this is the rheumatoid patient who has failed drug therapy, resulting in an arthritis mutilans appearance of the hands (remember that pencil-in-cup and arthritis mutilans are not exclusively seen in psoriatic arthritis). Another example is the Native American ankylosing spondylitis patient who is treated without the use of Western medications and may present not only with the spondyloarthropathy expected in ankylosing spondylitis, but also with erosive disease involving all the peripheral joints, including hands and feet. Finally, the classic disease process that may be confusing is end-stage gout, which, if misdiagnosed or undertreated, may result in spectacular erosive disease at unexpected locations. It is important to remember that gout can look like anything and can be located at any joint!

## Coexistence of Arthritic Processes

It is not unusual for two of the more common arthritic processes to coexist, particularly in the elderly patient. This may be confusing initially but can be worked out through understanding the prevalence of the diseases in the patient population, as well as by paying attention to the appearance and location of the abnormalities present. The most common combination is a new onset of rheumatoid arthritis superimposed on osteoarthritis. In this case, the osteoarthritis is usually well-established, involving the 1st carpometacarpal and interphalangeal joints in classic fashion, but there is new inflammatory change seen in the metacarpophalangeal joints. The elderly patient may also develop pyrophosphate arthropathy, superimposed over osteoarthritis or rheumatoid arthritis. The patient with a diabetic Charcot joint may develop superimposed septic arthritis. Keeping these possibilities in mind is useful to the interpreter, as the pattern of disease may not be classic.

## Conclusion

There are many subtleties involved at specific joint locations in specific diseases, which cannot be discussed in such a broad introduction. These will be covered in proper detail in the individual sections that follow.

## Selected References

1. Haavardsholm EA et al: Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. *Ann Rheum Dis.* 67(6):794-800, 2008
2. Kim NR et al: "MR corner sign": value for predicting presence of ankylosing spondylitis. *AJR Am J Roentgenol.* 191(1):124-8, 2008



## INTRODUCTION TO ARTHRITIS

## Characteristics of Arthritic Processes

Arthritis Type	Gender Predominance	# of Joints	Symmetry	Bone Density	Character of Process	Cartilage Destruction
RA	M < F (1:3)	Polyarticular	Yes, by end stage	Density ↓	Erosive	Early, diffuse
Robust RA	M > F	Polyarticular	Yes, by end stage	End stage ↓	Erosive	Early, diffuse
JIA	M < F (1:4-5)	Pauci- or polyarticular	Generally no	End stage ↓	Erosive	Early, diffuse
Hemophilia	M only	Pauciarticular	No	Normal	Erosive	Early, diffuse
Adult Still disease	M = F	Polyarticular	Generally no	End stage ↓	Erosive	Early, diffuse
Multicentric reticulohistiocytosis	M < F	Polyarticular	Yes	Related to age	Erosive	Early, diffuse
Osteoarthritis	M < F	Polyarticular	Often	Normal	Produces bone	Early, focal
DISH/OPLL	M > F (2:1)	Nonarticular	Nonarticular	Normal	Produces bone	None
AS/IBD arthritis	AS: M > F (2.5-5:1); IBD: M = F	Polyarticular	Yes, by end stage	Mid- to end stage ↓	Mixed	Midstage, diffuse
PSA/CRA/HIV arthritis	PSA: M = F; CRA/ HIV: M > F (5-6:1)	Polyarticular	Generally no	Normal	Mixed	Midstage, diffuse
Gout	M > F (9:1)	Polyarticular	No	Normal	Mixed	Late disease
Pyrophosphate arthropathy	M < F (1:2-7)	Polyarticular	Generally no	Related to age	Mixed	Midstage, diffuse
Hemochromatosis	M only	Polyarticular	Generally no	Normal	Produces bone	Late disease
Amyloid	M > F	Pauciarticular	No	Density ↓	Erosive	Early, focal
PVNS	M < F (1:2)	Monoarticular	No (single joint)	Normal	Erosive	Late, focal
PSC	M > F	Monoarticular	No (single joint)	Normal	Erosive	Late, focal
Charcot	M = F, relates to etiology	Mono- or pauciarticular	No	Not unless diabetic	Destructive	Early, diffuse
Septic arthritis	M = F	Monoarticular	No (single joint)	Normal	Erosive	Early, diffuse

## Characteristics of Arthritic Processes

Arthritis Type	Subchondral Cysts	Enthesopathy	Periostitis	Adjacent Density	Ankylosis	Soft Tissue Masses
RA	Yes	No	No	No	No	Rheumatoid nodules
Robust RA	Yes, large	No	No	No	No	Rheumatoid nodules
JIA	Yes	No	Yes, early	No	Yes	No
Hemophilia	Yes	No	No	No	No	No
Adult Still disease	Yes	No	No	No	Yes	No
Multicentric reticulohistiocytosis	Yes	No	No	No	No	Nodules
Osteoarthritis	Yes	Yes	No	Rare chondrocalcinosis	No	Heberden nodes
DISH/OPLL	No	Yes, prominent	No	No	Yes	No
AS/IBD arthritis	Yes	Yes, prominent	No	No	Yes	No
PSA/CRA/HIV arthritis	Yes	Yes	Yes, prominent	No	Yes	No
Gout	Yes	No	No	Yes, tophus	No	Tophi
Pyrophosphate arthropathy	Yes, large	No	No	Chondrocalcinosis	No	No
Hemochromatosis	Yes	No	No	Chondrocalcinosis	No	No
Amyloid	Yes, large	No	No	No	No	Amyloid nodules
PVNS	Yes, large	No	No	No	No	No
PSC	Yes	No	No	Calcified bodies	no	Rare extraarticular
Charcot	Yes	No	Occasionally	Osseous debris	No	Large fluid collections
Septic arthritis	If chronic	No	Yes	No	Rare	No

Abbreviations: Rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), diffuse idiopathic skeletal hyperostosis (DISH), ossification posterior longitudinal ligament (OPLL), ankylosing spondylitis (AS), inflammatory bowel disease (IBD), psoriatic arthritis (PSA), chronic reactive arthritis (CRA), pigmented villonodular synovitis (PVNS), & primary synovial chondromatosis (PSC).